0 Items
Select Page

Legionella

The bacterium L. pneumophila was first identified in 1977, as the cause of an outbreak of severe pneumonia in a convention centre in the USA in 1976. It has since been associated with outbreaks linked to poorly maintained artificial water systems, particularly cooling towers or evaporative condensers associated with air conditioning and industrial cooling, hot and cold water systems in public and private buildings, and whirlpool spas.

 

Our monoclonal antibodies and native antigen can be used in support of assay development and R&D into Legionella infection. We also provide a novel system for species-specific detection and labeling of L. pneumophila which can be used with a range of tags for purification and microscopic imaging.

Legionella background

L. pneumophila is an opportunistic intracellular pathogen that was first recognised in a group of individuals, presenting with a lung infection, who had attended a convention in Philadelphia in 1976. It is the causative agent of a severe type of pneumonia referred to as Legionnaires’ disease. The symptoms of Legionnaires’ disease include shortness of breath, cough, headache, fever and muscle ache, which can occur 2 – 10 days after exposure. Complications associated with infection may result in death. L. pneumophila may also cause a mild form of disease known as Pontiac fever, which is self-limiting and doesn’t require hospitalisation (CDC). Both forms of the disease may also be referred to as Legionellosis.

Legionella Antigens

We are pleased to offer a native extract of inactivated Legionella pneumophila antigen taken from culture. No vaccine is currently available for legionellosis and it is hoped that these reagents will enable the research community to develop new serological assays and vaccine candidates for future use.

Legionella Immunoassays

The Native Antigen Company are pleased to provide both ELISA assays and chemical reporters which can be used for detection of Legionella phneumophila.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

A Q&A with David Flavell of Leukaemia Busters

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in...

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...

The Bumpy Road to a Cytomegalovirus Vaccine

The development of a cytomegalovirus vaccine has been 50 years in the making. Are there any technologies in the pipeline that could prompt a breakthrough? This article was originally posted online at The Medicine Maker, a Texere publication.To say that...

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

5 + 2 =

Live Customer Feedback

Join our mailing list

* indicates required